

**table (1):** Socio demographic characteristics and clinical data of patients in different studied groups (N. =90)

Parameter	Malignant tumor (N=60)	Benign tumor (N=15)	Healthy control (N=15)	P-value
Age Mean± S.D. Median (Range)	35.53± 12.96 33(23 – 60)	44.2± 16.94 45 (18 -75)	55± 13.68 55 (20 – 75)	<0.001□
Sex Males (%) Female s (%)	22 (36.7%) 38 (63.3%)	5 (33.3%) 10 (66.7%)	7 (46.7%) 8 (53.3%)	.718□□
Family history Negative (%) Positive (%)	41 (68.3%) 19 (31.7%)	13 (86.7%) 2 (13.3%)	--	.136□□
Urea mg/dl Mean± S.D. Median (Range)	20.9± 7.9 16 (13 – 36)	20.6 ± 7.5 17 (14 – 34)	23.1± 6.06 27 (14 – 34)	0.570
Uric acid mg/dl Mean± S.D. Median (Range)	2.7 ± 1.2 2 (1.4 – 5.9)	2.9 ± 0.9 2.7 (1.9 – 4.2)	2.9 ± 0.9 2.7 (1.8 – 4.2)	0.140
Creatinine Mean± S.D. Median (Range)	0.8 ± 0.2 0.8 (0.2 – 1)	0.8 ± 0.2 0.8 (0.6 –1)	0.7± 0.2 0.7 (0.5 – 1)	0.196
Alkaline phosphatase IU/l Mean± S.D. Median (Range)	89.1± 7.2 90 (70 – 99)	91.5 ± 3.7 90 (87 – 99)	86.8 ± 9.2 90 (70 – 99)	0.594
AST IU/l Mean± S.D. Median (Range)	19.9 ± 7.3 21 (0.5 – 33)	24.5 ± 7.6 27 (10 – 33)	22.9 ± 4.9 23 (20 – 40)	0.017□
ALT IU/l Mean± S.D. Median (Range)	16.6 ± 4.5 16 (6 – 23)	23.4 ± 5.2 23 (16 – 34)	19.3 ± 7.4 18 (13 – 45)	0.000□
HB g/dl Mean± S.D. Median (Range)	10.02 ± 2.04 9.8 (5.5 – 13)	10.3 ± 2.4 9.9 (7.6 – 15.1)	12.5 ± 2.01 13 (7.7 – 15)	0.000□
RBCs×10 <sup>6</sup> /ul Mean± S.D. Median (Range)	4.2 ± 0.8 4.1 (2.6 – 5.5)	3.9 ± 1.6 4.6 (1.2 – 5.6)	4.9 ± 0.5 4.9 (3.6 – 5.5)	0.052
WBCs×10 <sup>3</sup> /ul Mean± S.D. Median (Range)	10.02 ± 4.2 9.2 (5.5 – 17.6)	8.7 ± 2.5 8 (5.5 – 14.2)	8.9 ± 2.3 8 (5.8 – 14.6)	0.789
Platelets ×10 <sup>3</sup> /ul Mean± S.D. Median (Range)	354.5 ± 121.5 345 (219 – 617)	306.3 ± 62.1 299 (220 – 400)	291.1 ± 81.4 250 (220 – 486)	0.108

**Table (2):** Comparison of Thymidine phosphorylase and Annexin A3 levels among the study groups

Thymidine phosphorylase Units/ml	Healthy control (N= 60)	Benign tumor (N= 15)	Malignant tumor (N= 15)	P-value	P1	P2	P3
Mean± S.D. Median (Range)	29.09± 5.73 27.3 (19.3 – 35.6)	70.85± 4.59 70.6 (65.1 -77.1)	147.64± 13.33 147 (123.2 – 171.3)	<0.001*	<0.001*	<0.001*	<0.001*
Annexin A3 Pg/ml							
Mean± S.D. Median (Range)	67.68± 14.36 70.2 (34.4 – 80.9)	162.31± 20.33 165 (134.9 -198)	997.68± 542.62 1100 (200 – 1780)	<0.001*	<0.001*	<0.001*	<0.001*

**Table (3):** Comparison of Thymidine phosphorylase and Annexin A3 according to tumor burden (N. = 60)

Enzyme	High (N= 23)	Low (N= 37)	P-value
Thymidine phosphorylase (Units/ml) Mean± S.D. Median (Range)	153.42± 12.59 152.6 (130.2 – 171.3)	144.05 ± 12.64 146.5 (123.2 – 169.9)	0.022*
Annexin A3(Pg/ml) Mean± S.D. Median (Range)	1429.65 ± 326.32 1500 (599 – 1780)	729.16± 473.51 500 (200 – 1700)	0.000*

**Table (4):** Comparison of Thymidine phosphorylase level and Annexin A3 according to tumor grading (N. = 60)

Thymidine phosphorylase	Grade 2 (N= 22)	Grade 3 (N= 18)	Grade 4 (N=20)	P-value
Mean± S.D. Median (Range)	141.9± 11.4 146.5 (123.2 – 163.4)	146.9± 13.9 147.3 (126.8 -169.9)	154.5± 12.1 154.3 (136.8 – 171.3)	0.035*
Annexin A3				
Mean± S.D. Median (Range)	342.6± 125.5 330 (200 – 600)	1171± 124.6 1150 (1000 - 1500)	1562.3± 149.3 1585 (1334 - 1780)	<0.001*

**Table (5):** Correlation between Thymidine phosphorylase and Annexin A3 levels in all the studied groups (n=90).

Enzyme	Annexina3	
	r	P-value
Thymidine phosphorylase	0.791	<0.001*

**Table (6):** Correlation between Thymidine phosphorylase and Annexin A3 levels among the three studied group (n= 90).

Group	r	P-value
Malignant tumor group	0.311	0.016*
Benign tumor group	0.320	0.245
Control group	0.513	0.051

